Huo Xiang Zheng Qi Oral Liquid Combined with 5-HT3 Receptor Antagonists and Dexamethasone Can Prevent Chemotherapy-Induced Nausea and Vomiting for Patients Receiving Multiday Cisplatin-Based Regimen: A Multicenter Trial

医学 化疗引起恶心呕吐 养生 恶心 呕吐 地塞米松 内科学 临床终点 安慰剂 不利影响 随机对照试验 止吐药 麻醉 替代医学 病理
作者
Hao Wei,Yu Sun,Lingling Xie,Yuming Jia,Jun He,Xiaofei Deng,Wei Huang,Yang Hu,Jiang Zhu
出处
期刊:Journal of integrative and complementary medicine [Mary Ann Liebert]
卷期号:29 (8): 501-509 被引量:3
标识
DOI:10.1089/jicm.2022.0672
摘要

Background: Chemotherapy-induced nausea and vomiting (CINV) is one of the most distressing side effects associated with deterioration in the quality of life. This study aimed to assess the clinical value of Huoxiang Zhengqi (HXZQ) oral liquid, a Chinese patent medicine, in combination with 5-HT3 receptor antagonists (RAs) and dexamethasone, in preventing CINV in patients receiving multiday cisplatin-based chemotherapy. Methods: In this multicenter, exploratory randomized clinical trial, the authors compared the efficacy of HXZQ oral liquid against a control group receiving a placebo, in combination with 5-HT3 RAs and dexamethasone, in preventing CINV in chemotherapy-naive patients receiving a multiday cisplatin-based regimen between January 2021 and September 2021. The primary endpoint was the complete response (CR) rate. The secondary endpoints included days with no CINV, the incidence of CINV, and life function. Results: Sixty patients were randomized into two groups and included in the study. The CR rate was significantly improved by HXZQ oral liquid in acute CINV (63.33% vs. 33.33%, p = 0.020) and CINV beyond the risk phase (96.67% vs. 46.67%, p = 0.000). The number of days with no CINV was significantly more in the HXZQ group compared with the control group in the overall phase (18.10 ± 3.64 vs. 12.13 ± 7.63, p = 0.002). Significantly higher Functional Living Index-Emesis total and domain scores were observed in the HXZQ group. Conclusions: HXZQ oral liquid combined with 5-HT3 RAs and dexamethasone is a feasible and safe approach to prevent CINV in patients receiving multiday cisplatin-based chemotherapy who cannot use neurokinin 1 RAs. Clinical Trial Registration: ChiCTR2000040123
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
Renee应助hihi采纳,获得10
1秒前
自然秋柳发布了新的文献求助10
4秒前
4秒前
Singularity应助咩咩咩采纳,获得10
4秒前
4秒前
源缘完成签到,获得积分10
5秒前
淡然的汉堡完成签到,获得积分10
6秒前
匆匆完成签到,获得积分10
6秒前
6秒前
6秒前
小伙子完成签到,获得积分20
6秒前
tanrui完成签到,获得积分10
6秒前
feng完成签到 ,获得积分10
7秒前
qqqqq发布了新的文献求助10
7秒前
8秒前
8秒前
白佐帅完成签到,获得积分20
8秒前
炙热松思关注了科研通微信公众号
9秒前
9秒前
彭洪泽完成签到,获得积分10
9秒前
Nina发布了新的文献求助10
10秒前
qin希望应助minus采纳,获得10
11秒前
GEeZiii完成签到,获得积分10
11秒前
11秒前
12秒前
多发一区发布了新的文献求助10
12秒前
zZ发布了新的文献求助10
12秒前
风中的以寒完成签到,获得积分20
12秒前
13秒前
史道夫发布了新的文献求助10
13秒前
白佐帅发布了新的文献求助10
13秒前
huahua发布了新的文献求助10
14秒前
研友_LXO0R8发布了新的文献求助10
14秒前
14秒前
巴拉巴拉发布了新的文献求助10
15秒前
冷艳的海豚完成签到,获得积分10
17秒前
18秒前
EIS发布了新的文献求助10
18秒前
22秒前
高分求助中
Evolution 10000
ISSN 2159-8274 EISSN 2159-8290 1000
Becoming: An Introduction to Jung's Concept of Individuation 600
Ore genesis in the Zambian Copperbelt with particular reference to the northern sector of the Chambishi basin 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3160802
求助须知:如何正确求助?哪些是违规求助? 2811883
关于积分的说明 7893940
捐赠科研通 2470842
什么是DOI,文献DOI怎么找? 1315775
科研通“疑难数据库(出版商)”最低求助积分说明 631003
版权声明 602053